World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 8
Page: 614-620

THERAPEUTIC POTENTIAL OF AYURVEDIC *RASAYANA* THERAPY IN MITIGATING AGE-RELATED COGNITIVE DECLINE: AN INTEGRATIVE CLINICAL REVIEW

Dr. Syed Meer Faisal Ali.*[1], Dr Sandip Dilip Bansode[2], Dr Harun Babumiya Mujawar[3]

[1]M.D (Ayu), Reader / Asso professor, Department of Kaumarbhritya Balrog, Mups Ayurved college, hospital and Research center. Degaon, tq-Risod, Dist- Washim.

[2]M.D (Ayu), Assistant Professor, Department of Kayachikitsa, Dr K D Shendage Ayurvedic Medical College Omerga Tq Omerga Dist Dharashiv 413606.

[3]BAMS, MA (SANSKRIT), Assistant professor, Department of Sanskrit Samhita Siddhant, Dr K D Shendage Ayurvedic Medical College Omerga Tq Omerga Dist Dharashiv 413606.

Article Received: 25 June 2026 | | ***Article Revised: 16 July 2026*** | | ***Article Accepted: 06 July 2026***

***Corresponding Author: Dr. Syed Meer Faisal Ali.**
M.D (Ayu), Reader / Asso professor, Department of Kaumarbhritya Balrog, Mups Ayurved college, hospital and Research center. Degaon, tq-Risod, Dist- Washim. **DOI:** https://doi.org/10.5281/zenodo.21871725

How to cite this Article: Dr. Syed Meer Faisal Ali., Dr Sandip Dilip Bansode, Dr Harun Babumiya Mujawar (2026) THERAPEUTIC POTENTIAL OF AYURVEDIC *RASAYANA* THERAPY IN MITIGATING AGE-RELATED COGNITIVE DECLINE: AN INTEGRATIVE CLINICAL REVIEW. World Journal of Pharmaceutical Science and Research, 5(8), 614-620.

ABSTRACT

Age-related cognitive decline (ARCD) and neurodegenerative disorders such as Alzheimer's disease (AD) present significant therapeutic challenges for global healthcare systems. Traditional pharmacological strategies focus largely on symptomatic control rather than modifying underlying disease trajectories. Ayurvedic *Rasayana* therapy-a specialized branch of classical Indian medicine dedicated to tissue revitalization, longevity, and metabolic optimization-offers a multi-target, systemic paradigm for neuroprotection. *Medhya Rasayanas* (nootropic rejuvenators), including Bacopa monnieri (*Brahmi*), Withania somnifera (*Ashwagandha*), Centella asiatica (Mandukaparni), and 'Convolvulus pluricaulis' (*Shankhpushpi*), contain bioactive secondary metabolites that modulate cholinergic pathways, attenuate neuroinflammation, reduce \beta-amyloid cytotoxicity, and up regulate endogenous neurotrophic factors. This integrative clinical review synthesizes classical Ayurvedic concepts with modern neuropharmacological evidence, evaluating preclinical mechanisms, clinical efficacy, and systemic modes of action ('*Rasa'*, '*Agni'*, and '*Srotas'*) to establish an evidence-informed model for healthy cognitive aging.

KEYWORDS: Ayurvedic *Rasayana*, *Medhya Rasayana*, Age-Related Cognitive Decline, Neuroprotection, Integrative Medicine.

INTRODUCTION

Global population aging has driven an unprecedented rise in mild cognitive impairment (MCI), dementia, and related neurodegenerative pathologies. Pathophysiological hallmarks of cognitive decline include cumulative oxidative stress, chronic microglia activation, deregulated cholinergic transmission, synaptic loss, and pathological protein aggregation.[7]

Standard mono-targeted pharmaceuticals frequently yield modest efficacy and fail to arrest disease progression. Consequently, integrative healthcare approaches that target multiple pathological cascades simultaneously are gaining clinical interest. In Ayurveda, cognitive vitality is maintained through '*Rasayana Tantra*,[8] a medical discipline focused on slowing cellular senescence, enhancing immunity, and supporting systemic homeostasis.[6] Within this discipline, '*Medhya Rasayana*' formulations specifically target central nervous system preservation, intellectual acuity ('*Medha'*), and memory retention ('*Smriti'*).[12]

Fundamentals of Ayurvedic *Rasayana* & *Medhya Rasayana* Therapy

Classical Ayurvedic physiology posits that health is sustained through equilibrium among the three '*Doshas' ('Vata', 'Pitta', and 'Kapha')*, optimal digestive fire ('*Agni'*), and unobstructed microcirculatory channels ('*Srotas'*). Cognitive aging is predominantly driven by an aggravation of 'Vata Dosha', leading to tissue atrophy ('*Dhatu Kshaya*') and impaired micro perfusion.[11]

'Rasayana' interventions operate across three physiological levels

1. ''*Rasa* Level (Nutritional Enrichment):'' Directly enhancing the nutrient density of plasma and tissue fluids.
2. ''Agni Level (Metabolic Optimization):'' Stimulating cellular digestion and bioavailability of nutrients, thereby mitigating toxic metabolic byproducts ('*Ama'*).
3. ''*Srotas* Level (Micro-vascular Clearing):'' Enhancing microcirculation, blood-brain barrier integrity, and neural tissue perfusion.

'*Medhya Rasayanas*' act as brain tonics, balancing central '*Dosha'* dynamics while enhancing neuroplasticity and cellular repair mechanisms.[5]

NEUROPHARMACOLOGICAL MECHANISMS OF KEY NOOTROPIC BOTANICALS

Table 1: Showing Neuropharmacological Mechanisms of Key Nootropic Botanicals.

***Medhya Rasayana* Therapeutics**			
Bacopa monnieri	**Withania somnifera**	**Convolvulus pluricaulis**	**Centella asiatica**
(Bacosides A/B)	(Withanolides)	(Scopoletin)	(Asiaticosides)
AChE Inhibition	Aβ Fibril Inhibition	PTGS1/2 Modulation	Dendritic Sprouting
BDNF Upregulation	LRP1 Upregulation	Neurotransmitter Mod	Antioxidant Defenses
Microglial Control	Synaptic Repair	Memory Retention	Neuronal Longevity

I. 'Bacopa monnieri' (Brahmi) :

- 'Bacopa monnieri' is among the most thoroughly characterized 'Medhya Rasayanas'.[9] Its primary bioactive compounds, triterpenoid saponins known as bacosides A and B, cross the blood-brain barrier to exert neuroprotective and cognition-enhancing effects.[1]
- ''Cholinergic Modulation:'' Bacosides inhibit acetylcholinesterase (AChE) and enhance choline acetyltransferase (ChAT) activity, elevating cerebral acetylcholine concentrations crucial for memory acquisition and recall.[2]

‘‘Neuroprotection & Synaptic Plasticity:’’ ‘B. monnieri’ promotes protein kinase activity in the hippocampus, induces dendritic arborization, and upregulates brain-derived neurotrophic factor (BDNF).[1]

- ‘‘Antioxidant & Anti-Amyloid Effects:’’ ‘B. monnieri’ scavenges reactive oxygen species (ROS), restores endogenous antioxidant enzymes (glutathione, superoxide dismutase), and reduces cortical levels of \beta-amyloid 1-40 and 1-42 peptides in transgenic model systems.[2]

II. ‘Withania somnifera’ (Ashwagandha)

- ‘Withania somnifera’, a primary adaptogenic ‘*Rasayana’*, contains steroidal lactones (withanolides A–Y and withaferin A) that possess systemic anti-inflammatory, neuroprotective, and anti-stress properties.[3]
- ‘‘Inhibition of Amyloid-Beta Aggregation:’’ Bioactive withanamides bind to active motifs of \beta-amyloid peptides, blocking fibril assembly and protecting cortical neurons against A\beta-induced apoptosis.[3]
- ‘‘Clearance of Neurotoxic Plaques:’’ ‘W. somnifera’ up-regulates hepatic low-density lipoprotein receptor-related protein (LRP1), facilitating peripheral clearance of circulating \beta-amyloid and reversing pathological deficits in animal models of AD.[3]
- ‘‘Synaptic Regeneration:’’ Withanolide A promotes significant axonal and dendritic regeneration while restoring pre- and post-synapses damaged by neurotoxic insults.[3]

III. Convolvulus pluricaulis’ (Shankhpushpi)

- Traditionally prescribed to enhance intellect (‘Medha’) and calm nervous agitation, ‘Convolvulus pluricaulis’ exerts multi-target neuroprotective action against neurodegenerative cascades.[4]
- ‘‘Network Pharmacology Targets:’’ Phytochemical constituents such as scopoletin, kaempferol, and quercetin modulate prostaglandin G/H synthases (PTGS1, PTGS2), endothelial nitric oxide synthase (NOS3), and acetylcholinesterase (ACHE).[4]
- ‘‘Tau and Amyloid Suppression:’’ Preclinical data demonstrate that ‘C. pluricaulis’ attenuates mRNA and protein expressions of amyloid precursor protein (APP) and tau in experimental models, rescuing neurons from tau-induced neurotoxicity through reduction of neuroinflammation and oxidative stress.[4]

IV. ‘Centella asiatica’ (Mandukaparni) & ‘Clitoria ternatea’

- ‘‘Centella asiatica’:’’ Rich in asiaticosides and centellosides, this botanical stimulates neurite outgrowth, enhances hippocampal cell proliferation, and stabilizes mood and cognitive function in clinical models of MCI.[4]
- ‘‘Clitoria ternatea’:’’Possesses significant ‘Rasayana’ properties, promoting cellular differentiation,supporting DNA repair pathways, and enhancing central cholinergic tone.[6]

Summary of Neuropharmacological Targets

Table 2: Showing Summary of Neuropharmacological Targets.

Botanical Agent	Key Bioactive Constituents	Primary Neurobiological Mechanisms	Clinical / Translational Outcome
‘‘Brahmi’’ (‘Bacopa monnieri’)	Bacosides A & B, saponins	AChE inhibition, BDNF upregulation, antioxidant defense, microglial suppression	Improved visual processing, working memory, and delayed recall[2]
‘‘Ashwagandha’’ (‘Withania somnifera’)	Withanolides A–Y, withaferin A, withanamides	Blockade of A\beta fibrillogenesis, LRP1 upregulation,	Enhanced executive function, sustained attention, and immediate

		dendritic/axonal regeneration	memory in MCI[3]
"Shankhpushpi" ('Convolvulus pluricaulis')	Scopoletin, kaempferol, quercetin	Modulation of PTGS1/2, NOS3, AChE; attenuation of APP and tau protein expression	Improved cognitive flexibility, stress resilience, and attention span[4]
"Mandukaparni" ('Centella asiatica')	Asiaticoside, madecassoside	Neurite outgrowth, free radical scavenging, hippocampal neurogenesis support	Mood stabilization and memory retention in age-related cognitive decline[5]

TRANSLATIONAL INSIGHTS & INTEGRATIVE CLINICAL PROTOCOLS

The translation of 'Rasayana' therapy into contemporary clinical practice involves integrating botanicals with bio-cleansing procedures ('Panchakarma') and personalized dietary regimens.

i. Panchakarma Integration

- Classical protocols frequently combine '*Medhya Rasayanas*' with targeted 'Panchakarma' therapies to clear systemic channels ('*Srotas'*) before administering rejuvenative remedies:
- ***Nasya Karma* (Intranasal Administration)**: [13] Transmucosal administration of medicated oils (e.g., '*Anu Taila*') through the nasal passages facilitates direct delivery across the olfactory mucosa, bypassing the blood-brain barrier.
- **Basti Karma (Therapeutic Enemas):**[13] Regulates central '*Vata Dosha*' via the gut-brain axis, modulating gut microbiota composition and reducing systemic neuroinflammation.

ii. Clinical Evidence in Humans

- Human trials support the efficacy of standardized '*Rasayana'* extracts in treating cognitive impairments,[3]
- 'A prospective, randomized, double-blind, placebo-controlled study evaluating 300 mg twice daily of 'Withania somnifera' root extract over 8 weeks demonstrated significant improvements in immediate and general memory, executive function, and information processing speed in patients with MCI.[3]
- 'Double-blind trials examining standardized 'Bacopa monnieri' extract (300 mg/day) over 12 weeks revealed significant enhancements in working memory, visual information processing, and learning rates among aging adults,[2]

CHALLENGES, SAFETY, AND FUTURE DIRECTIONS

While Ayurvedic 'Rasayana' therapies display considerable neurotherapeutic potential, several challenges impede widespread clinical adoption:

1. **"Standardization & Quality Control**:" Variability in phytochemical content due to geographical origin, harvesting time, and extraction protocols necessitates standardized fingerprinting (e.g., HPLC, LC-MS).
2. **"Bioavailability:"** Phytochemicals like withanolides and bacosides exhibit limited oral bioavailability. Classical lipid-based delivery systems ('*Ghritas'* / medicated ghee) enhance trans-barrier transport and bioavailability.
3. **"Rigorous Clinical Validation:"** Large-scale, multi-center randomized controlled trials (RCTs) incorporating neuroimaging (fMRI, PET) and fluid biomarkers (\beta-amyloid 42/40 ratio, phosphorylated tau, BDNF) are required to establish long-term efficacy and safety profiles.

MATERIAL AND METHOD

- This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive systematic search was executed across four electronic databases—PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar—spanning literature published from January 2000 through May 2024.
- Classical Correlation: Textual analysis of classical Ayurvedic treatises (*Charaka Samhita, Sushruta Samhita, and Astanga Hridaya)* was conducted to cross-map concepts of Dosha imbalance (Vata dominance in aging), Agni degradation, and *Srotas* blockages with modern pathological features of neurodegeneration.
- Network Pharmacology Synthesis: Molecular targets of identified primary bioactive secondary metabolites (e.g., Bacoside A, Withanolide A, Scopoletin, Asiaticoside) were mapped against neuroinflammatory, cholinergic, and amyloid cascades to generate the multi-target mechanistic framework presented in this review.

DISCUSSION

The findings synthesized in this review demonstrate that Ayurvedic 'Rasayana' therapy[10]—specifically through '*Medhya Rasayana'* formulations—offers a plausible, multi-target framework to address the complex aetiology of age-related cognitive decline (ARCD) and early-stage neurodegenerative disorders. Modern neurobiology increasingly acknowledges that single-target pharmacological interventions often fall short in arresting disease progression in complex pathologies such as Alzheimer's disease (AD). In contrast, the network pharmacology of phytoconstituents found in 'Bacopa monnieri', 'Withania somnifera', 'Convolvulus pluricaulis', and 'Centella asiatica' aligns well with the multi-systemic paradigm required to preserve cognitive longevity.

A key strength of the 'Rasayana' approach lies in its ability to simultaneously target distinct yet intersecting pathophysiological cascades:

- ''Cholinergic and Neurotrophic Modulation:'' Phytochemicals like bacosides from 'B. monnieri' enhance central cholinergic tone while upregulating brain-derived neurotrophic factor (BDNF), supporting synaptic plasticity and memory retention.[3]
- ''Amyloid-Beta and Tau Proteostasis:'' Withanolides from 'W. somnifera' and constituents of 'C. pluricaulis' interfere with \beta-amyloid aggregation, facilitate peripheral clearance through hepatic LRP1 upregulation, and attenuate tau-mediated cellular toxicity.[3]
- ''Neuroinflammation and Oxidative Stress:'' The broad-spectrum antioxidant and microglial-modulating activities across these botanicals mitigate the self-perpetuating cycle of neuroinflammation and ROS-induced neuronal injury.[7]

From a translational perspective, bridging Ayurvedic theoretical constructs with neurovascular and neuroendocrine pathways provides a coherent framework for integrative protocols. The classical levels of action- *'Rasa'* (nutritional enrichment), 'Agni' (metabolic optimization), and 'Srotas' (microvascular clearing)-correlate directly with modern physiological targets: systemic nutrient delivery, mitochondrial and metabolic efficiency, and blood-brain barrier (BBB) integrity alongside microvascular perfusion.

Furthermore, combining these botanicals with specialized delivery strategies highlights the sophisticated nature of traditional formulations. The use of lipid-based carriers ('Ghritas' / medicated ghee) addresses the limited oral

bioavailability of hydrophobic molecules like withanolides and bacosides, facilitating improved transit across the BBB. Similarly, adjunct classical procedures like ‘Nasya’ (intranasal delivery) utilize olfactory pathways to target the central nervous system directly, bypassing first-pass metabolism and BBB restriction.

LIMITATIONS AND CRITICAL CONSIDERATIONS

Despite compelling preclinical evidence and encouraging preliminary human trials, several obstacles remain before these therapies can be fully incorporated into standard clinical guidelines:

1. **“Heterogeneity in Clinical Trial Design:”** Many clinical studies on ‘Medhya Rasayanas’ feature relatively small sample sizes, brief follow-up durations (typically 8 to 12 weeks), and variable clinical endpoints. Long-term studies evaluating sustained disease modification over years are still lacking.
2. **“Standardization and Quality Control:”** Phytochemical variations driven by geographic sourcing, seasonal harvesting, and extraction methodologies pose significant challenges to batch-to-batch reproducibility. Standardized fingerprinting (via HPLC/LC-MS) and uniform bioactive profiling are essential prerequisites for regulatory approval.
3. **“Mechanistic Biomarker Validation:”** While functional and cognitive scale improvements (e.g., memory and executive function tests) are documented, future research must routinely integrate validated fluid biomarkers (such as plasma A\beta_{42/40} ratios, phosphorylated tau, and neurofilament light chain) and advanced neuroimaging (fMRI, PET) to objectively confirm neurostructural preservation and amyloid/tau clearance in human cohorts.

Addressing these gaps through well-powered, multi-center randomized controlled trials will be crucial to transitioning Ayurvedic ‘Rasayana’ protocols from complementary care options into validated, mainstream neuroprotective therapies for healthy cognitive aging.

CONCLUSION

Ayurvedic ‘*Rasayana’* therapy represents a multi-targeted therapeutic framework for mitigating age-related cognitive decline.[11] Rather than operating via single-receptor blockade, ‘*Medhya Rasayanas’* act synergistically across cellular, metabolic, and systemic networks to reduce oxidative stress, attenuate neuroinflammation, modulate cholinergic neurotransmission, and foster neuroplasticity[1,4] Integrating standardized ‘*Rasayana’* botanicals into modern clinical workflows offers a promising strategy for preserving cognitive longevity and managing early-stage neurodegenerative conditions.

REFERENCES

1. Abdul Manap, A. S., Vijayabalan, S., Madhavan, P., Chia, Y. Y., Arya, A., Wong, E. H., Rizwan, F., Bindal, U., & Koshy, S., ‘Bacopa monnieri’, a neuroprotective lead in Alzheimer disease: A review on its properties, mechanisms of action, and preclinical and clinical studies. ‘Drug Target Insights’, 2019; 13: 117739281986641. https://doi.org/10.1177/1177392819866412 (15 JULY 2026 : 2 pm)
2. Aguiar, S., & Borowski, T., Neuropharmacological review of the nootropic herb ‘Bacopa monnieri’. ‘Rejuvenation Research’, 2013; 16(4): 313–326. https://doi.org/10.1089/rej.2013.1431 (15 JULY 2026 : 2 pm)
3. Gregory, J., Vengalasetti, Y. V., Bredesen, D. E., & Rao, R. V., Neuroprotective herbs for the management of Alzheimer’s disease. ‘Biomolecules’, 2021; 11(4): 543. https://doi.org/10.3390/biom11040543 (15 JULY 2026 : 2 pm)

4. Hannan, M. A., Sultana, A., Rahman, M. H., Al Mamun Sohag, A., Dash, R., Uddin, M. J., Hossen, M. J., & Moon, I. S. (2022). Protective mechanisms of nootropic herb Shankhpushpi (‘Convolvulus pluricaulis’) against dementia: Network pharmacology and computational approach. ‘Evidence-Based Complementary and Alternative Medicine’, 2022; 1–18. https://doi.org/10.1155/2022/1015310 (15 JULY 2026 : 2 pm)
5. Mehla, J., Gupta, P., Pahuja, M., Diwan, D., & Diksha, D., Indian medicinal herbs and formulations for Alzheimer’s disease, from traditional knowledge to scientific assessment. ‘Brain Sciences’, 2020; 10(12): 964. https://doi.org/10.3390/brainsci10120964
6. Prasad, K., Raghu, K. S., Maruthiyodan, S., Wadhwa, R., Kaul, S. C., Satyamoorthy, K., & Guruprasad, K. P., Promotion of cellular differentiation and DNA repair potential in brain cancer cells by ‘Clitoria ternatea’ L. with rasayana properties in vitro. ‘Journal of Ayurveda and Integrative Medicine’, 2025; 16: 101050. https://doi.org/10.1016/j.jaim.2024.101050 (15 JULY 2026 : 2 pm)
7. Tripathi, P., Lodhi, A., Rai, S., Nandi, N., Dumoga, S., Yadav, P., Tiwari, A., Singh, S., El-Shorbagi, A.-N., & Chaudhary, S., Review of pharmacotherapeutic targets in Alzheimer’s disease and its management using traditional medicinal plants. ‘Degenerative Neurological and Neuromuscular Disease’, 2024; 14: 47–74. https://doi.org/10.2147/dnnd.s452009.
8. Sushrut Samhita by Dr.Anant Ram Sharma, Sushrutavimarini hindi commentary chukahamba surbaharati prakashana, Varanasi, Sutra Stan, Adhaya no.1, Verse no.15, Page No.7.
9. Agnivesha.charak samhita, chikitsa stan.elaborated by charaka and redacted by dridbala, edited with ‘vaidyamanorama’ hindi commentery by pro.P.V.Sharma. Reprint by chubhmba orientalia vol-2, Chikitsa Stan, Adhaya no.1, Verse-30-32, Page No.24-25.
10. Vagbahata, Ashatang Rudhaya by Pro.K.R.Shrikanta Murthy, chukhmba publication,krishandas academy, Adhaya no.39, Verse no.44-45, Page No.380-386.
11. Sushrut Samhita by Dr.Anant Ram Sharma, Sushrutavimarini hindi commentary chukahamba surbaharati prakashana, Varanasi, Sutra Stan, Adhaya no.35, Verse no.29, Page No.278.
12. Sushrut Samhita by Dr.Anant Ram Sharma, Sushrutavimarini hindi commentary chukahamba surbaharati prakashana, Varanasi, chikitsa Stan, Adhaya no.28, Verse no.1-28, Page No.388-395.
13. Sushrut Samhita by Dr.Anant Ram Sharma, Sushrutavimarini hindi commentary chukahamba surbaharati prakashana, Varanasi, chikitsa Stan, Adhaya no.40, Verse no.2-6, Page No.498-500.